Applying Sharpness-Aware Minimization (SAM) to convolutional neural networks trained on raw MALDI-TOF mass spectrometry data yields a higher classification accuracy for antibiotic resistance in S. aureus than standard Adam optimization, ruling out the rival account that SAM's generalization benefits are specific to optical Raman spectral features.

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Spine & Adversarial Read

“This hypothesis tests whether Sharpness-Aware Minimization improves CNN classification accuracy for antibiotic resistance detection from raw MALDI-TOF mass spectrometry data compared to standard Adam optimization, independent of the Raman-specific spectral modality in which SAM's generalization benefit was originally reported.”

• highWhy CNNs specifically, rather than gradient-boosted trees or simpler logistic regression, which are the established state-of-the-art baselines on DRIAMS (Weis et al. 2022 found LightGBM competitive with deep learning on MALDI data)? The methodology choice of CNN+SAM may be optimizing a comparison that isn't the relevant one for clinical deployment.
  The EVP should include a LightGBM/logistic regression baseline arm to contextualize whether SAM-CNN exceeds the actual clinical SOTA, not just Adam-CNN. This is not yet included in the protocol and must be added before results are considered methodologically complete; currently this is a gap.
• mediumThe claim that SAM's benefit is not 'optical Raman-specific' requires that the original Raman finding and this MALDI finding use genuinely comparable pipelines (same architecture family, same tuning rigor); if the Raman control replication uses a different architecture or preprocessing than the original paper, failure to replicate could be attributed to pipeline mismatch rather than true modality-dependence, undermining the ruling-out claim.
  Mitigated by Step 6 (exact pipeline replication) but full fidelity (identical architecture, hyperparameter ranges, preprocessing) to the original Raman study cannot be guaranteed without access to that study's code/data, which was not available in the search results used to build this EVP; this is an acknowledged gap given zero live search results for prior art.
• medium2 percentage point accuracy improvement threshold for 'success' may not be clinically meaningful given DRIAMS resistance base rates and existing AUROC already >0.80 in published baselines — a small statistical improvement may not translate into fewer missed MRSA cases in practice.
  Should be paired with clinical decision-curve analysis (net benefit at various resistance-prevalence thresholds) rather than accuracy/AUROC alone; this refinement is not yet in the protocol and should be added in a follow-up iteration.

Experimental Protocol

ROI Projection

Implementation Sketch

# Pseudocode
for optimizer in [SAM, Adam]:
    for seed in range(10):
        for fold in outer_cv(5):
            model = ResNet1D(input_dim=6000, n_classes=2)
            best_hp = bayes_opt_inner_cv(model, optimizer, fold.train)
            if optimizer == SAM:
                opt = SAM(base_optimizer=SGD, rho=best_hp.rho, lr=best_hp.lr)
                train_loop: 
                    loss = criterion(model(x), y)
                    loss.backward(); opt.first_step()
                    criterion(model(x), y).backward(); opt.second_step()
            else:
                opt = Adam(lr=best_hp.lr, weight_decay=best_hp.wd)
                train_loop: standard forward/backward/step
            metrics[optimizer][seed][fold] = evaluate(model, fold.test)
compare(metrics[SAM], metrics[Adam])  # paired stats
sharpness[optimizer] = hessian_top_eigenvalue(model, fold.test)
replicate_on_raman_control()
external_validate(best_models, independent_cohort)